All Type of News
Intensified polarization in R&D investment among listed pharms
Although it is estimated there were more than 6 listed pharmaceutical companies investing more than KRW 100 billion into R&D in a year, there were also a number of pharmaceutical products spending less than 1% of thei...
No updates for settling balance for differences on targeted therapy for cancer ‘Tarceva’
The pharmaceutical distribution industry raised complaints since they have not been able to settle balance for differences generated by the drug price cut of ‘Tarceva,’ a Roche Korea’s targeted therapy for cancer.
Th...
Celltrion records KRW 196.6 billion sales and KRW 89.4 billion operating profits
Celltrion announced on the 11th that it recorded KRW 196.578 billion sales in the 1st quarter of 2017, increased by 81.2% compared to the same quarter of the last year.
Its operating profits were KRW 89.394 billion i...
MOU for cooperation between Korea-Japan medical device associations
The Korea Medical Devices Industry Association(Chairman Hui Hwang, KMDIA) announced it signed a memorandum of understanding(MOU) for co-development of the two countries’ medical device industry with the Japan Federati...
Rep. Seung-Hee Kim, “The key of ‘reasonable benefits, reasonable burden’ is how to make financial resources”
While the 19th President Jae-In Moon administration is expected to make changes in the health care policies, Rep. Seung-Hee Kim(Health & Welfare Committee) at the Liberty Korea Party, which has become an opposing part...
‘Zemiglo’ license lawsuit meets new phase with Sanofi’s marketing data
At a lawsuit between LG Life Sciences and Sanofi-Aventis over close of the Zemiglo’s license, it seems a new phase is going to be developed as Sanofi turned in data about its marketing activity.
The Civil Affairs Dep...
Distribution field sensitive on EZmedicom’s action to have direct business with pharmas
The pharmaceutical distribution industry has had concerns about some pharmaceutical companies showing movements to have a direct business with EZmedicom.
According to the industry concerned on the 15th, it was told E...
Daewoong, “There has been no Nabota counterfeit distributed in Korea so far’Daewoong Pharmaceutical(CEO Jong-Wook Lee) announced the company was working on distribution of ‘Nabota’ counterfeits on the 12th and revealed an intermediate result that there ...
|
Alvogen Korea’s KRW 4.49 billion sales in 1st quarter, recording losses for the quarterAlvogen Korea announced on the 15th it recorded KRW 44.91 billion sales in the 1st quarter of 2017, decreased by 1.4% compared to the same quarter of the last year.
The company...
|
Merz Korea signs business agreement of ‘Contractubex’ with C&C HealthcareFollow by the business agreement for ‘Pantogar’ last March, Merz Korea is newly launching an OTC drug business by selecting a new partner for ‘Contractubex,’ a scar treatment.
...
|
